



ESC Congress 2010
28 August - 1 September, Stockholm, Sweden

Please return this form to: ESC / Industry Services Department
The European Heart House, 2035 Route des Colles, Les Templiers, BP 179
06903 Sophia Antipolis FRANCE
Email: satellite@escardio.org - Fax: +33(0)4 92 94 76 26

SATELLITE AND MINI-SATELLITE SYMPOSIA SCIENTIFIC FORM
DEADLINE 31 MARCH 2010

SATELLITE SYMPOSIUM N°

MINI SATELLITE SYMPOSIUM N°

The identification of your Satellite Symposium or Mini-Satellite Symposium corresponds to a Session Number assigned the moment you apply.

This number must be included in all communications by the Satellite organisers and their appointed agencies in order to have a concise working relationship.

In order to eliminate confusion and miscommunication, mails that do not contain this Session Number will not be immediately treated.

Session Title:

Full name of ACRONYMS and ABBREVIATIONS mandatory / No PRODUCT NAMES or BRAND NAMES are allowed.

Organised by:

Duration: minutes

Name of the company(ies) to be printed in all Programmes

Primary Topic:

MANDATORY: ESC Congress 2010 Topic list attached at the end of this form.

CHAIRPERSONS:

2 Chairpersons are mandatory for Satellite Symposia and Mini Satellite Symposia

1. CHAIRPERSON

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

2. CHAIRPERSON

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

SUMMARY:

Please summarise your scientific session content (10 lines max)
This summary will not be printed in any ESC publications.

--

PRESENTATIONS, TOPIC, DURATION and SPEAKERS:

Please refer to regulations at the end of this form

INTRODUCTORY AND CONCLUDING REMARKS PRESENTATIONS ARE MANDATORY

1. PRESENTATION / SPEAKER

Topic:	Title: <i>INTRODUCTORY PRESENTATION IS MANDATORY</i>	Duration:
---------------	---	------------------

Full name of ACRONYMS and ABBREVIATIONS mandatory / No PRODUCT NAMES or BRAND NAMES are allowed.

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

2. PRESENTATION / SPEAKER

Topic:	Title:	Duration:
---------------	---------------	------------------

Full name of ACRONYMS and ABBREVIATIONS mandatory / No PRODUCT NAMES or BRAND NAMES are allowed.

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

3. PRESENTATION / SPEAKER

Topic:	Title:	Duration:
---------------	---------------	------------------

Full name of ACRONYMS and ABBREVIATIONS mandatory / No PRODUCT NAMES or BRAND NAMES are allowed.

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

4. PRESENTATION / SPEAKER

Topic:	Title:	Duration:
---------------	---------------	------------------

Full name of ACRONYMS and ABBREVIATIONS mandatory / No PRODUCT NAMES or BRAND NAMES are allowed.

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

5. PRESENTATION / SPEAKER

Topic:	Title:	Duration:
---------------	---------------	------------------

Full name of ACRONYMS and ABBREVIATIONS mandatory / No PRODUCT NAMES or BRAND NAMES are allowed.

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

6. PRESENTATION / SPEAKER

Topic:	Title:	Duration:
---------------	---------------	------------------

Full name of ACRONYMS and ABBREVIATIONS mandatory / No PRODUCT NAMES or BRAND NAMES are allowed.

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

7. PRESENTATION / SPEAKER

Topic:	Title:	Duration:
---------------	---------------	------------------

Full name of ACRONYMS and ABBREVIATIONS mandatory / No PRODUCT NAMES or BRAND NAMES are allowed.

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

8. PRESENTATION / SPEAKER

Topic:	Title:	Duration:
---------------	---------------	------------------

Full name of ACRONYMS and ABBREVIATIONS mandatory / No PRODUCT NAMES or BRAND NAMES are allowed.

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

9. PRESENTATION / SPEAKER

Topic:	Title:	Duration:
---------------	---------------	------------------

Full name of ACRONYMS and ABBREVIATIONS mandatory / No PRODUCT NAMES or BRAND NAMES are allowed.

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

10. PRESENTATION / SPEAKER

Topic:	Title:	Duration:
---------------	---------------	------------------

Full name of ACRONYMS and ABBREVIATIONS mandatory / No PRODUCT NAMES or BRAND NAMES are allowed.

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

11. PRESENTATION / SPEAKER

Topic:	Title:	Duration:
---------------	---------------	------------------

Full name of ACRONYMS and ABBREVIATIONS mandatory / No PRODUCT NAMES or BRAND NAMES are allowed.

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

12. PRESENTATION / SPEAKER

Topic:	Title:	Duration:
---------------	---------------	------------------

Full name of ACRONYMS and ABBREVIATIONS mandatory / No PRODUCT NAMES or BRAND NAMES are allowed.

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

13. PRESENTATION / SPEAKER

Topic:	Title:	Duration:
---------------	---------------	------------------

Full name of ACRONYMS and ABBREVIATIONS mandatory / No PRODUCT NAMES or BRAND NAMES are allowed.

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

14. PRESENTATION / SPEAKER

Topic:	Title:	Duration:
---------------	---------------	------------------

Full name of ACRONYMS and ABBREVIATIONS mandatory / No PRODUCT NAMES or BRAND NAMES are allowed.

Title:	Family name:	First name:
Dept/Inst./Company:		
Address:		
Postal code:	City:	Country:
Tel:	Fax:	E-mail:

CHAIRPERSONS:

- Two "chairpersons" per session are mandatory.
- Must be available until the end of the session.
- One of the two Chairpersons can give a presentation.
- Cannot chair or speak another session at the same time.
- At least one Chairperson should have expert knowledge about the topic.
- Both Chairpersons should be fluent in English.
- Please mention the **First names and Last names** of the chairpersons and be sure to give their full titles, first and last names, phone, fax numbers and email address.

First names are used to match people when checking.

If name and addresses are not given, no checking (for example, for simultaneous sessions) will be done and index entries may be wrong or missing.

PRESENTATIONS:

- **Please add full name of acronyms and abbreviations.**
- Introductory and Concluding presentations are mandatory
- NO PRODUCT NAMES or BRAND NAMES are allowed.
- These should include the break (for 180-minute sessions) and any scheduled discussions, panels, closing remarks etc.

TOPIC:

- If not present, the "primary topic" will be used.
- If you do not supply an index topic, neither your session nor the individual presentations will appear in the indexes of the Final Programme.

DURATION:

- In minutes.
- **Regulations concerning the exact number of Speakers and the duration of each presentation have been relaxed. While allowing greater flexibility the ESC stresses that the sessions should still be organised in a way that will allow adequate discussion and presentation.**

SPEAKERS:

- Please do not forget the **First name & Last name** and address of each speaker. The institution will not be printed in the programme.
- Must be available until the end of the session.
- Cannot speak twice in the same session.
- Cannot speak another session at the same time.
- No more than half of the speakers should come from the same country.
- Should be fluent in English.

CHANGE IN THE SCIENTIFIC PROGRAMME / ERRATUM POLICY:

Once the title, programme and detailed content are approved, changes must not be made without the specific approval of the Congress Programme Committee.

The ESC kindly asks the Company to inform them of any modifications to the Scientific Programme before **4 May 2010** in order to be printed in the Final Programme.

Any changes must be approved by the Congress Programme Committee.

Late applications and/or content of programmes received after 4 May 2010 cannot be printed in the Final Programme.

Details received between 4 May 2010 and 30 July 2010 will appear in the ERRATUM.

Only changes of the title of the session, the name of the session organizer, the day, the room and the time will appear in the ERRATUM.

Changes in the scientific programme of Satellite Symposia or Mini-Satellite Symposia content (presentations titles, name and details of faculties...) are not mentioned in the ERRATUM.

Failure to adhere to announced/approved programme content will be considered a violation of Guidelines for Industry Participation.

When sending us the Satellite Symposia or Mini-Satellite Symposia Scientific forms, you confirm that you have received the prior approval of faculties for providing us the above data.

Extract from ESC DATA PRIVACY AND SECURITY POLICY

"Disclosure of Information and Marketing

The ESC complies with EC directives, and is registered under the data protection laws in France, and takes all reasonable care to prevent any unauthorised access to your personal data. Our ESC staff and contractors have a responsibility to keep your information confidential.

The ESC does not sell, trade, or rent your personal information to others. We may supply your information to trusted ESC contractors to perform specific services. Otherwise, we do not disclose personal information to any other person or organisation without your consent.

If you are a delegate at an ESC organised Congress or meeting, when you visit exhibiting company stands, presenting your badge may enable them to retrieve the following personal data: first name(s), last name(s), address, telephone, fax, email, and professional activity information."

"Disclosure of Conflict of Interest

The session organiser confirms that All Speakers/Chairpersons participating in this programme have fully agreed to provide the session organiser with any potential conflicts of interest that may arise from their presentations.

The existence of potential conflicts of interest does not necessarily indicate a bias. However it is the session organiser's obligation to inform the ESC and participants so that they are made aware of any relationship that might cause unintentional bias.

A potential conflict of interest may arise from various relationships, past or present, such as employment, consultancy, investments and stock ownership, funding for research, family relationship, etc...

A potential bias relevant to the topic of the accredited programme/text must be disclosed:

- at the beginning of the presentation for events*
- on the introductory page of the CD ROM or Web module*
- at the beginning or at the end of the CME article/text*

TOPIC LIST ESC CONGRESS 2010 - Spotlight 2010: 'Coronary Artery Disease: From Genes to Outcomes': indicated by *

<p><u>1. Arrhythmias</u></p> <p><u>Arrhythmias / Pacing / Resynchronisation</u></p> <p>101 Mechanisms of arrhythmias</p> <p>102 Genetic aspects of arrhythmias</p> <p>103 Electrocardiography</p> <p>104 Non invasive studies</p> <p>105 Invasive electrophysiological studies</p> <p>106 Atrial fibrillation (AF)</p> <p>107 Supraventricular arrhythmias (excluding AF)</p> <p>108 Ventricular arrhythmias</p> <p>109 Sudden death / resuscitation</p> <p>110 Syncope</p> <p>111 Antiarrhythmic drugs</p> <p>112 Catheter ablation</p> <p>113 Cardioversion / defibrillation</p> <p>114 Antibradycardia pacing</p> <p>115 Automatic implantable cardioverter / defibrillator</p> <p>116 Resynchronisation therapy</p>	<p><u>Myocardial-Pericardial disease</u></p> <p>3.11 Cardiomyopathies</p> <p>3.12 Myocarditis</p> <p>3.13 Pericardial disease / Tumours</p> <p>3.14 Pericardial and myocardial disease, other</p> <p>3.15 Infectious and parasitic diseases</p> <p>3.16 Nutritional heart diseases</p> <p><u>Congenital heart disease / Pediatric cardiology</u></p> <p>3.17 Morphology, pathology and genetics</p> <p>3.18 Grown-up congenital heart disease and surgery</p> <p>3.19 Fetal cardiology</p> <p>3.20 Imaging and intervention</p> <p>3.21 GUCH and paediatric cardiology others</p> <p>3.22 Pregnancy and heart disease</p>	<p><u>Peripheral circulation/stroke</u></p> <p>5.11 Pathophysiology, epidemiology, diagnosis</p> <p>5.12 Invasive / medical treatment</p> <p>5.13 Stroke</p> <p><u>Cardiovascular surgery</u></p> <p>*5.14 CAD surgery</p> <p>5.15 Valvular heart disease surgery</p> <p>*5.16 Minimal invasive and Robotic Surgery</p> <p>5.17 Aorta, peripheral arterial and venous surgery</p> <p>*5.18 Heart transplantation and LV assist devices</p>	<p><u>Pharmacology and pharmacotherapy</u></p> <p>7.08 Drug therapy</p> <p>7.09 Guidelines and Implementation in low resource settings</p> <p>7.10 Pharmacogenomics</p>
<p><u>2. Heart Failure / LV dysfunction</u></p> <p><u>heart failure / LV dysfunction</u></p> <p>2.01 Pathophysiology and diagnosis</p> <p>2.02 Pharmacologic therapy</p> <p>2.03 Neurohormones</p> <p>2.04 Medical aspects of transplantation</p> <p>2.05 Basic mechanisms</p> <p>2.06 Cardiac surgery</p> <p>2.07 Diastolic dysfunction</p> <p>2.08 Ventricular function/hemodynamics</p> <p>2.09 Peripheral circulation, metabolism and skeletal muscle</p> <p>2.10 Prognosis</p> <p>2.11 Heart failure, other</p>	<p><u>4. Ischaemia / CAD / ACC</u></p> <p><u>Thrombosis & platelets, microcirculation</u></p> <p>*4.01 Thrombosis and platelets</p> <p>*4.02 Inflammation and microcirculation</p> <p><u>Ischaemia / ACS / infarction</u></p> <p>*4.03 Ischaemia, experimental studies</p> <p>*4.04 Angina pectoris stable</p> <p>*4.05 Angina pectoris unstable</p> <p>*4.06 Infarction acute phase STEMI</p> <p>*4.07 Infarction acute phase non STEMI</p> <p>*4.08 Post infarction period</p> <p>*4.09 Adjunctive medical therapy</p> <p>*4.10 Antithrombotic agents</p> <p>*4.11 Thrombolysis and mechanical reperfusion</p> <p>*4.12 CAD and comorbidities</p> <p><u>Acute cardiac care</u></p> <p>*4.13 CPR (Cardiopulmonary resuscitation)</p> <p>*4.14 Acute cardiac care, other</p>	<p><u>6. Prevention / Rehabilitation / Sports / Nursing</u></p> <p><u>Basic and translational science</u></p> <p>6.01 Basic and translational science</p> <p><u>Sports cardiology</u></p> <p>6.02 Exercise testing and training</p> <p>6.03 Sports cardiology</p> <p><u>Prevention and rehabilitation</u></p> <p>6.04 Primary cardiovascular prevention: interventions and outcomes</p> <p>6.05 Secondary cardiovascular prevention: interventions and outcomes</p> <p>6.06 Cardiovascular rehabilitation: interventions and outcomes</p> <p><u>Epidemiology and health policy</u></p> <p>6.07 Physical activity</p> <p>6.08 Tobacco</p> <p>6.09 Diabetes, dysglycaemia and metabolic syndrome</p> <p>6.10 Psycho-social</p> <p>6.11 Nutrition</p> <p>6.12 Overweight, obesity and central obesity</p> <p>6.13 Social, economic and cultural</p> <p>6.14 Cardiovascular risk</p> <p>6.15 Public health and health policy</p> <p>6.16 Vital and other statistics</p> <p>6.17 Cost-effectiveness</p> <p><u>Nursing</u></p> <p>6.18 Acute nursing care</p> <p>6.19 Chronic nursing care</p>	<p><u>8. Basic Science</u></p> <p><u>Cardiovascular system (patho)physiology</u></p> <p>8.01 Developmental biology</p> <p>8.02 Cardiovascular anatomy and pathology</p> <p>8.03 Integrative physiology and control mechanisms</p> <p>8.04 Stem cells and cell therapy</p> <p>8.05 Genetics and gene therapy</p> <p><u>Cardiac cellular biology</u></p> <p>8.06 Metabolism and metabolic syndromes</p> <p>8.07 Ischemia and protection</p> <p>8.08 Hypertrophy, cell cycle and apoptosis</p> <p>8.09 Growth factors, neurohormones and signal transduction-cardiac</p> <p>8.10 Excitation-contraction coupling and contractile remodeling</p> <p>8.11 Ion channels and electrophysiology</p> <p>8.12 Cardiac biology, other</p> <p><u>Vascular biology</u></p> <p>8.13 Angiogenesis</p> <p>8.14 Lipids</p> <p>8.15 Atherosclerosis</p> <p>8.16 Endothelial function</p> <p>8.17 Inflammation, growth factors and signal transduction-vascular</p> <p>8.18 Vascular remodeling</p> <p>8.19 Vascular biology, other</p>
<p><u>3. Valvular disease / Pulmonary circulation / Myocardial-Pericardial disease/Congenital heart disease & Pediatric cardiology</u></p> <p><u>valvular disease</u></p> <p>3.01 Aortic valve disease</p> <p>3.02 Mitral valve disease</p> <p>3.03 Endocarditis</p> <p>3.04 Surgery and intervention in valve disease</p> <p>3.05 Valvular heart disease, other</p> <p>3.06 Rheumatic heart disease</p> <p><u>pulmonary circulation</u></p> <p>3.07 Acute pulmonary embolism</p> <p>3.08 Chronic pulmonary hypertension</p> <p>3.09 Right ventricular function</p> <p>3.10 Pulmonary circulation, other</p>	<p><u>5. Interventions / Peripheral Circulation / Stroke / Surgery</u></p> <p><u>Coronary circulation</u></p> <p>*5.01 Physiology, hemodynamics and microcirculation</p> <p>*5.02 Invasive coronary imaging</p> <p>*5.03 Vulnerable plaque</p> <p><u>Interventional cardiology</u></p> <p>*5.04 PCI: pre-clinical studies</p> <p>*5.05 PCI/Stents: devices and technique</p> <p>*5.06 PCI: procedural complications</p> <p>*5.07 PCI: lesion/patient subsets</p> <p>*5.08 PCI: longterm outcome</p> <p>5.09 Non coronary cardiac interventions</p> <p>*5.10 Restenosis</p>	<p><u>7. Hypertension / Pharma</u></p> <p><u>Hypertension</u></p> <p>7.01 Autonomic nervous system and humoral regulations</p> <p>7.02 Haemodynamics, heart and hypertension</p> <p>7.03 Treatment of hypertension</p> <p>7.04 Ambulatory pressure monitoring</p> <p>7.05 Hypertension, other</p> <p>7.06 Hypertension: Regional and ethnic profiles</p> <p>7.07 Hypertension and diet</p>	<p><u>9. Cardiac Imaging / Computers</u></p> <p><u>Nuclear cardiology. CMR & CT</u></p> <p>9.01 Scintigraphy (SPECT)</p> <p>9.02 Positron emission tomography (PET)</p> <p>9.03 Cardiovascular Magnetic Resonance (CMR)</p> <p>9.04 X-ray Computed tomography (CT)</p> <p>9.05 Imaging, other</p> <p><u>Echocardiography / Doppler</u></p> <p>9.06 Echo-ventricular function</p> <p>9.07 Echo-valvular heart disease</p> <p>9.08 Echo-contrast / tissue characterization</p> <p>9.09 Stress echo</p> <p>9.10 Echo/Doppler, other</p> <p><u>Computers in cardiology</u></p> <p>9.11 ECG and arrhythmia analysis</p> <p>9.12 Internet and Telemedicine</p> <p>9.13 Image processing and DICOM</p> <p>9.14 Computers and databases</p>